Danish multinational diabetes care giant Novo Nordisk (NOV: N) has submitted a New Drug Application (NDA) for faster-acting insulin aspart, it has been announced.
The submission is based on the results from the ‘onset’ clinical trial program which involved more than 2000 people with type 1 and type 2 diabetes.
The onset program is a Phase III clinical program with faster-acting insulin aspart consisting of four trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze